1. Home
  2. LOOP vs BOLD Comparison

LOOP vs BOLD Comparison

Compare LOOP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

N/A

Current Price

$0.52

Market Cap

39.7M

Sector

Industrials

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.83

Market Cap

60.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LOOP
BOLD
Founded
2010
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
60.8M
IPO Year
2010
2024

Fundamental Metrics

Financial Performance
Metric
LOOP
BOLD
Price
$0.52
$2.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
1.4M
233.9K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
27.27
32.47
EPS
N/A
N/A
Revenue
$10,889,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$174.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7016.99
N/A
52 Week Low
$0.55
$0.96
52 Week High
$1.99
$3.16

Technical Indicators

Market Signals
Indicator
LOOP
BOLD
Relative Strength Index (RSI) 27.01 59.74
Support Level N/A $2.71
Resistance Level $0.97 $2.97
Average True Range (ATR) 0.07 0.13
MACD -0.00 -0.02
Stochastic Oscillator 2.60 30.56

Price Performance

Historical Comparison
LOOP
BOLD

About LOOP Loop Industries Inc.

Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: